SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap

Ify R. Mordi; Rory J. McCrimmon; Chim C. Lang

doi:10.1161/circulationaha.124.069695

SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap

I Ify R. Mordi (School of Medicine, University of Dundee, United Kingdom (I.R.M., R.J.M., C.C.L.).) R Rory J. McCrimmon (School of Medicine, University of Dundee, United Kingdom (I.R.M., R.J.M., C.C.L.).) C Chim C. Lang (School of Medicine, University of Dundee, United Kingdom (I.R.M., R.J.M., C.C.L.).)

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Circulation

Volume / Issue Vol. 151, Issue 3

Published January 21, 2025

Pages 199-201

DOI 10.1161/circulationaha.124.069695

ISSN 0009-7322

Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (3)

I

Ify R. Mordi

School of Medicine, University of Dundee, United Kingdom (I.R.M., R.J.M., C.C.L.).

R

Rory J. McCrimmon

School of Medicine, University of Dundee, United Kingdom (I.R.M., R.J.M., C.C.L.).

C

Chim C. Lang

School of Medicine, University of Dundee, United Kingdom (I.R.M., R.J.M., C.C.L.).

SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap

Article Details

Journal Info

Authors (3)

Related Articles from this Journal

Occupational Radiation Safety in Electrophysiology During Pregnancy: Evaluating Uterine Radiation Doses During Catheter Ablations and Device Implantations

Response by Rogers et al to Letter Regarding, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”

Clinical Cardiology at the Crossroads: Perspectives on the Next Era at <i>Circulation</i>

ABHD11-Mediated mtDNA Transcription Restored Mitochondrial Function to Attenuate Cardiomyocyte Ferroptosis After Myocardial Infarction

Letter by Li et al Regarding Article, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”